Anti-angiogenesis methods, compositions and uses therefor

Details Anti-angiogenesis methods, compositions and uses therefor Anti-angiogenesis methods, compositions and uses therefor

2007-07-31

2007-07-31

Saidha, Tekchand (Department: 1652)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S183000, C435S219000, C435S320100, C530S350000, C536S023200

Reexamination Certificate

active

10304287

ABSTRACT:
This invention relates generally to methods of producing peptide-based anti-angiogenesis compounds using plasmin reductases, and specifically to methods of producing an A61anti-angiogenic plasmin fragment using an annexin II heterotetramer or subunit thereof. This invention also relates to anti-angiogenesis methods and compositions comprising a plasmin reductase or polynucleotides encoding subunits thereof. Compositions useful for the inhibition or promotion of angiogenesis are also disclosed.

REFERENCES:
patent: 4462980 (1984-07-01), Diedrichsen et al.
patent: WO 02/44328 (2002-06-01), None
Soffa. Cancer Metastasis Rev. Jun. 2000; 19(1-2):97-107.
Kassam et al. J Biol Chem. Feb. 20, 1998; 273(8):4790-4799.
Kassam et al. Biochemistry. Dec. 1, 1998;37(48):16958-66.
Kwon et al. J Biol Chem. Mar. 29, 2002;277(13):10903-10911.
Kassam et al. J Biol Chem. Mar. 23, 2001; 276(12): 8924-8933.
Gately et al. Proc. Natl. Acad. Sci. USA. Sep. 1997; 94: 10868-10872.
Ballagamba et al., Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding,J. Biol. Chem. 272: 3195-3199, Feb. 7, 1997.
Brooks et al., Ca2+-dependent, phospholipids independent binding of annexin 2 to annexin 6,Biochem. J. manuscript No. BJ20020997, Jul. 25, 2002.
Cao et al., Kringle domains of human angiostatin,J. Biol. Chem. 271 29461-29467, Nov. 15, 1996.
Choi et al., Annexin II tetramer inhibits plasmin-dependent fibrinolysis,Biochemistry31: 648-655, Jan. 13, 1998.
Choi et al., Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer,J. Biol. Chem. 276: 25212-25221, Jul. 6, 2001.
Falcone et al., Macrophage formation of angiostatin during inflammation,J. Biol. Chem. 273 31480-31485, Nov. 20, 1998.
Filipenko and Waisman, Characterization of the Ca2+-binding sites of annexin II tetramer,J. Biol. Chem. 275: 38877-38884, Dec. 8, 2000.
Filipenko and Waisman, The C terminus of annexin II mediates binding to F-actin,J. Biol. Chem. 276: 5310-5315, Feb. 16, 2001.
Fitzpatrick et al., Regulation of plasmin activity by annexin II tetramer,Biochemistry39: 1021-1028, Jan. 14, 2000.
Fitzpatrick et al., Fucidan-dependent conformational changes in annexin II tetramer,Biochemistry39: 2140-2148, Feb. 10, 2000.
Fogg et al., The p11 subunit of annexin II heterotetramer is regulated by basic carboxypeptidase,Biochemistry41: 4953-4961, Mar. 20, 2002.
Gately et al., The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin,PNAS94: 10868-10872, Sep. 1997.
Johnsson and Weber, Alkylation of cysteine 82 of p11 abolishes the complex formation with the tyrosine-protein kinase substrate p36,J. Biol. Chem. 265: 14464-14468, Aug. 25, 1990.
Kang et al., Characterization of human recombinant annexin II tetramer purified from bacteria: Role of N-terminal acetylation,Biochemistry36: 2041-2050, Jan. 15, 1997.
Kassam et al., Characterization of the heparin binding properties of annexin II tetramer,J. Biol. Chem. 272: 15093-15100, Jun. 13, 1997.
Kassam et al., The role of annexin II tetramer in the activation of plasminogen,J. Biol. Chem. 273: 4790-4799, Feb. 20, 1998.
Kassam et al., The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation,Biochemistry37: 16958-16966, Nov. 5, 1998.
Kassam et al., Purification and characterization of A61,J. Biol. Chem. 276: 8924-8933, Mar. 23, 2001.
Kwon et al., P22 is a novel plasminogen fragment with antiangiogenic activity,Biochemistry40: 13246-13253, Oct. 13, 2001.
Kwon et al., Identification of annexin II heterotetramer as a plasmin reductase,J. Biol. Chem. 277: 10903-10911, Mar. 29, 2002.
Lay et al., Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase,Nature408: 869-873, Dec. 14, 2000.
Stathakis et al., Generation of angiostatin by reduction and proteolysis of plasmin,J. Biol. Chem. 272: 20641-20645, Aug. 15, 1997.
Stathakis et al., Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin,J. Biol. Chem. 274: 8910-8916, Mar. 26, 1999.
Teratani et al., Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma,Cancer Lett. 175: 71-77, Jan. 2002.
Caplan et al, “Regulation of annexin A2 by reversible glutathionylation.” J Biol Chem., 2004, vol. 279, No. 9, pp. 7740-7750.
Choi et al., “p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells.” FASEB J., 2003, vol. 17, No. 2, pp. 235-246.
Filipenko et al., “Annexin A2 is a novel RNA-binding protein.” J Biol Chem., 2004, vol. 279, No. 10, pp. 8723-8731
Fitzpatrick et al., “Regulation of plasmin activity by annexin II tetramer.” Biochemistry, 2000, vol. 39, No. 5, pp. 1021-1028.
Heidtmann et al., “Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen.” Br J Cancer, 1999, vol. 81, No. 8, pp. 1269-1273.
MacDonald et al., “The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3.” Biochem Biophys Res Commun., 1999, vol. 264, No. 2, pp. 469-477.
MacLeod et al., “Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin.” J Biol Chem., 2003, vol. 278, No. 28, pp. 25577-25584.
Menhart et al., “Construction, expression, and purification of recombinant kringle 1 of human plasminogen and analysis of its interaction with omega-amino acids.” Biochemistry, 1991, vol. 30, No. 7, pp. 1948-1957.
Yao et al., “Dexamethasone alters arachidonate release from human epithelial cells by induction of p11 protein synthesis and inhibition of phospholipase A2 activity.” J Biol Chem., 1999, vol. 274, No. 24, pp. 17202-17208.
Zhang et al., “RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells.” J Biol Chem., 2004, vol. 279, No. 3, pp. 2053-2062.

Affiliated with

Also associated with

Rating

Anti-angiogenesis methods, compositions and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-angiogenesis methods, compositions and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-angiogenesis methods, compositions and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3806988